Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
Conditions
Catheter Site Discomfort - Complications - Anesthesia - Urinary Bladder Neoplasms
Conditions: official terms
Urinary Bladder Neoplasms
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Intervention
Name: Glycopyrrolate Type: Drug
Name: Atropine Type: Drug
Overall Status
Recruiting
Summary
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
Detailed Description
The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways.

We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 19 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients scheduled for transurethral bladder excision under general anesthesia

- ASA I-III

Exclusion Criteria:

- Foley catheter less than 18 Fr.

- Patients with obstruction of urinary tract

- Patients with neurogenic bladder

- Patients with severe obesity

- Patients with neurologic disorder

- Patients with chronic pain

- Patients with allergic history to atropine or glycopyrrolate
Location
Seoul National University of Hospital
Seoul, Korea, Republic of, Korea, Republic of
Status: Recruiting
Contact: Hee-Pyoung Park, PhD - +82-10-2971-7647 - hppark@snu.ac.kr
Start Date
September 2014
Completion Date
March 2015
Sponsors
Seoul National University Hospital
Source
Seoul National University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page